Skip to content
★ Sign in to follow
Total declarations
12
Companies
2
▲ Purchases (10 ops.)
€43k
▼ Sales (0 ops.)
—

Latest filing published 18 Mar 2016 for Capricor Therapeutics, INC., €4,537.

Insider track record

Disclosed buys
10
Disclosed sells
0
Signal history

No signal scores available.

Closed purchases

Market purchases
10
Positive at T+90
50%
Median T+90
-5.5%

Based on 8 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Leland Gershell: trading record in brief

Leland Gershell is a declared insider at 2 companies; the most frequent names are Tonix Pharmaceuticals Holding Corp. and Capricor Therapeutics, Inc. Between 26 April 2013 and 16 March 2016, the trades on record add up to 12 filings.

The open-market record is one-sided, with 10 purchases worth €43k and not one sale. No amount is published for 1 filing, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant. In 2016 alone, the filings show 1 purchase and no sales.

A typical purchase (the median) is worth €1,296. Looking at 8 purchases old enough to measure, the stock rose over the following 90 days in 50% of cases; the median change was -5.5%. These figures describe past trades and do not predict future prices.

The latest filing, published on 18 March 2016, reports an open-market purchase of €4,537 in Capricor Therapeutics, Inc. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Leland Gershell

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations11 total

11 of 11 declarations